[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Rutigliano DN, Meyers P, Ghossein RA, Carlson DL, Kayton ML, Kraus D, La Quaglia MP: Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma. J Pediatr Surg; 2007 Jul;42(7):E9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma as a secondary malignancy in pediatric sarcoma.
  • PURPOSE: Children diagnosed with osteosarcoma (OS) and Ewing sarcoma (ES) have greatly benefited from the addition of alkylator therapy.
  • To our knowledge, this is the first series of mucoepidermoid carcinomas arising in pediatric patients treated for sarcoma without radiotherapy.
  • METHODS: Long-term survivors of OS and ES currently undergoing routine follow-up care were reviewed and noted for the development of a new secondary malignancy.
  • RESULTS: Two patients, a 17-year-old adolescent boy with OS and 16-year-old adolescent girl with ES, with secondary mucoepidermoid carcinoma of the parotid gland were identified.
  • Both patients underwent primary resection and chemotherapy including alkylating agents, but neither received radiation.
  • CONCLUSION: Primary mucoepidermoid carcinoma of the parotid gland accounts for less than 10% of all head and neck tumors in childhood.
  • Previous series of secondary mucoepidermoid carcinoma have demonstrated an increased risk in patients with leukemia/lymphoma.


2. Sava┼čan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y: CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma; 2006 Oct;47(10):2076-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
  • This study compared immunophenotypic and drug sensitivity patterns of childhood AMKL cases with or without DS.
  • In children without DS, high expression of CD36 on AMKL blasts identified a sub-group with immunophenotypic and drug sensitivity patterns similar to that of DS AMKL.
  • CD36 expression in acute myeloid leukemia cases other than AMKL was not associated with increased in vitro drug sensitivity.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Cell Membrane / metabolism. Child. Child, Preschool. Cytarabine / pharmacology. Daunorubicin / pharmacology. Down Syndrome / complications. Humans. Immunophenotyping. Infant. Infant, Newborn. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2004-5 [17071466.001]
  • (PMID = 17071479.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / U10 CA 30969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD36; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


3. Settin A, Al Haggar M, Al Dosoky T, Al Baz R, Abdelrazik N, Fouda M, Aref S, Al-Tonbary Y: Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura Egypt. Hematology; 2007 Apr;12(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura Egypt.
  • Initially low HB < 8 gm/dl, high WBCs and platelet counts >50.000/mm(3) also showed better but non-significant remission rates.
  • Our conclusions were that cytogenetic and molecular characterizations of childhood ALL could add prognostic criteria for proper therapy allocation.
  • [MeSH-major] Aneuploidy. Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Drug Resistance, Neoplasm. Egypt / epidemiology. Female. Genetic Markers. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Infant. Karyotyping. Male. Neoplasm, Residual. Prognosis. Remission Induction. Risk Factors


Advertisement
4. Settin A, Al Haggar M, Al Dosoky T, Al Baz R, Abdelrazik N, Fouda M, Aref S, Al-Tonbary Y: Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt. Hematology; 2006 Oct;11(5):341-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic cytogenetic markers in childhood acute lymphoblastic leukemia: cases from Mansoura, Egypt.
  • Initially low Hb < 8 gm/dl, high WBCs and platelet counts > 50,000/mm(3) also showed better but non-significant remission rates.
  • CONCLUSIONS: Cytogenetic and molecular characterizations of childhood ALL may add prognostic criteria for optimal therapy allocation.
  • [MeSH-major] Cytogenetic Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Biomarkers. Bone Marrow Examination. Child. Child, Preschool. Chromosome Aberrations. Drug Resistance, Neoplasm. Egypt. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Infant. Male. Prognosis. Remission Induction


5. Kang R, Tang DL, Cao LZ, Yu Y, Zhang GY, Xiao XZ: [High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell]. Zhonghua Er Ke Za Zhi; 2007 May;45(5):329-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High mobility group box 1 is increased in children with acute lymphocytic leukemia and stimulates the release of tumor necrosis factor-alpha in leukemic cell].
  • OBJECTIVE: Cytokine mediated cell immunity is the main mode of anti-tumor immunity in organism, and the disequilibrium of cytokine network is the main cause of tumor cells escaping immunologic surveillance.
  • In the present study, the investigators explored the clinical significance of alteration in the serum levels of HMGB1 in childhood acute lymphocytic leukemia (ALL) and the mechanism of HMGB1-induced tumor necrosis factor (TNF)-alpha secretion in leukemic cells.
  • METHODS: The serum levels of HMGB1 in healthy children and childhood ALL were assayed by Western blotting.
  • TNF-alpha started to become detectable at 2 h and was still increasing at 16 h after HMGB1 (1 microg/ml) treatment in K562 cell culture.
  • CONCLUSIONS: The measurement of serum HMGB1 is helpful to evaluate the prognosis of the childhood ALL.
  • [MeSH-major] HMGB1 Protein / metabolism. Imidazoles / pharmacology. JNK Mitogen-Activated Protein Kinases / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Cell Line, Tumor. Child. Cytokines / metabolism. Humans. Mitogen-Activated Protein Kinase Kinases / metabolism. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation. Signal Transduction / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697615.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / HMGB1 Protein; 0 / Imidazoles; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / SB 203580; 0 / Tumor Necrosis Factor-alpha; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


6. Baillargeon J, Langevin AM, Mullins J, Ferry RJ Jr, DeAngulo G, Thomas PJ, Estrada J, Pitney A, Pollock BH: Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2005 Dec;45(7):960-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transient hyperglycemia occurs commonly during the treatment for childhood acute lymphoblastic leukemia (ALL).
  • The purpose of this study was to examine the incidence of and risk factors for transient hyperglycemia during induction chemotherapy in Hispanic pediatric patients diagnosed with B-Precursor ALL.
  • PROCEDURE: The study cohort consisted of 155 Hispanic pediatric patients diagnosed with ALL and treated at one of two South Texas pediatric oncology centers between 1993 and 2002.
  • Hyperglycemia was defined as > or = 2 glucose determinations of > or = 200 mg/dl during the first 28 days of induction chemotherapy.
  • CONCLUSIONS: The incidence of chemotherapy-induced transient hyperglycemia in the present study cohort is comparable to that reported in previous pediatric ALL patients.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [Cites] Am J Dis Child. 1971 May;121(5):406-9 [5283023.001]
  • [Cites] J Nutr. 1998 Apr;128(4):701-6 [9521631.001]
  • [Cites] Am J Clin Nutr. 1994 Feb;59(2):307-16 [8310979.001]
  • [Cites] Diabetes Care. 1991 Feb;14(2):102-8 [2060411.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Feb;72(2):277-82 [1991798.001]
  • [Cites] N Engl J Med. 1986 Jul 24;315(4):215-9 [3523245.001]
  • [Cites] Eur J Clin Pharmacol. 1984;26(3):357-62 [6376142.001]
  • [Cites] J Pediatr. 1981 Jul;99(1):46-50 [6454771.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Jan;50(1):113-6 [7350174.001]
  • [Cites] J Clin Endocrinol Metab. 1969 Oct;29(10):1373-6 [5353665.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1179-85 [15022284.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1728-32 [12365956.001]
  • [Cites] J Diabetes Complications. 1996 Sep-Oct;10(5):243-5 [8887011.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):3051-5 [8768873.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4591-6 [10599724.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):671-80 [10699131.001]
  • [Cites] Arch Pediatr Adolesc Med. 2000 Aug;154(8):837-40 [10922283.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):225-43 [12350366.001]
  • (PMID = 15700246.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK002876-03; United States / NIDDK NIH HHS / DK / K08 DK002876; United States / NCI NIH HHS / CA / CA11078; United States / NIDDK NIH HHS / DK / K08 DK002876-03
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS293487; NLM/ PMC3102306
  •  go-up   go-down


7. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA: Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr; 2007 Apr;150(4):370-5, 375.e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • OBJECTIVE: To determine risk factors associated with reduced adult height in survivors of childhood acute lymphoblastic leukemia (ALL).
  • Attained adult height was determined among 2434 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 3009 siblings.
  • CONCLUSIONS: Survivors of childhood ALL are at increased risk of adult short stature, including those treated with chemotherapy alone.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Adolesc Med. 2002 Feb;13(1):161-9, viii [11841962.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] Int J Cancer. 2001;96 Suppl:117-24 [11992395.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2953-60 [12885815.001]
  • [Cites] Med Pediatr Oncol. 1985;13(1):14-21 [3871501.001]
  • [Cites] Am J Dis Child. 1987 May;141(5):550-2 [3578168.001]
  • [Cites] Arch Dis Child. 1987 Nov;62(11):1107-12 [3479948.001]
  • [Cites] Lancet. 1988 Feb 27;1(8583):460-2 [2893877.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):400-5 [1999710.001]
  • [Cites] Arch Dis Child. 1991 Dec;66(12):1403-7 [1776886.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Pediatr Res. 1993 Jun;33(6):577-82 [8378115.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] Arch Dis Child. 1994 Jun;70(6):472-5 [8048814.001]
  • [Cites] Acta Paediatr. 1994 Dec;83(12):1287-90 [7734872.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 May;17(2):167-71 [7749768.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1091-5 [8888924.001]
  • [Cites] Acta Paediatr. 1996 Sep;85(9):1096-101 [8888925.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):598-602 [9386666.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):351-6 [9589084.001]
  • [Cites] Eur J Pediatr. 1998 Sep;157(9):703-7 [9776525.001]
  • [Cites] Arch Dis Child. 1998 Aug;79(2):161-4 [9797600.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):139-43 [15714445.001]
  • [Cites] Nutr J. 2005;4:27 [16209706.001]
  • [Cites] Am J Dis Child. 1988 Nov;142(11):1199-202 [3177326.001]
  • [CommentIn] J Pediatr. 2007 Apr;150(4):332-4 [17382105.001]
  • (PMID = 17382112.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727-11; United States / NCI NIH HHS / CA / CA055727-11; United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / T32 CA009351; United States / NCI NIH HHS / CA / CA009351-27; United States / NCI NIH HHS / CA / U24-CA55727; United States / NCI NIH HHS / CA / T32 CA009351-27
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS21154; NLM/ PMC2766352
  •  go-up   go-down


8. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA: Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer; 2008 Apr;50(4):854-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.
  • BACKGROUND: The objective of this study was to determine risk factors associated with abnormal timing of menarche among survivors of childhood acute lymphoblastic leukemia (ALL).
  • PROCEDURE: Self-reported age of menarche was determined among 949 female ALL survivors participating in the Childhood Cancer Survivor Study (CCSS), a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 1,128 siblings.
  • Survivors treated with chemotherapy alone, including those exposed to alkylating agents, experienced menarche at a similar rate to siblings.
  • CONCLUSIONS: Few female childhood ALL survivors experienced menarche outside of the normal range.
  • Alkylating agent exposure was not associated with abnormal timing.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Menarche / drug effects. Menarche / radiation effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Radiotherapy / adverse effects


9. Gottardo NG, Baker DL, Willis FR: Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab. Pediatr Hematol Oncol; 2003 Oct-Nov;20(7):557-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Childhood autoimmune hemolytic anemia (AIHA) of the warm type is usually successfully managed with corticosteroids and/or immunoglobulin infusions.
  • Rituximab is an anti-CD20 (B-cell) monoclonal antibody used for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.
  • Case reports on the use of rituximab for childhood AIHA are scant.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Antibodies, Monoclonal / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. B-Lymphocytes / drug effects. Chronic Disease. Cyclosporine / therapeutic use. Female. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Infant. Prednisolone / therapeutic use. Recurrence. Remission Induction / methods. Rituximab. Splenomegaly. Time

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12959862.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 83HN0GTJ6D / Cyclosporine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down






Advertisement